Author

W. A. Yu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

K. S. Carmon· 2 shared Q. J. Liu· 2 shared S. Park· 2 shared J. Cui· 1 shared J. Tu· 1 shared L. Wu· 1 shared S. Zhang· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

K. S. Carmon

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Drug Conjugates of Antagonistic RSPO4 Mutant For Simultaneous Targeting of LGR4/5/6 for Cancer Treatment

J. Cui, S. Park, W. A. Yu, K. S. Carmon, Q. J. Liu

This paper develops RSPO4 mutant-based peptibody drug conjugates that target LGR4/5/6, showing potent cytotoxic effects and tumor suppression in vitro and in vivo.

bioRxiv · Feb 5, 2021 · PreprintPharmacology & Toxicology

The most common RNF43 mutant G659Vfs41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis

J. Tu, S. Park, W. A. Yu, S. Zhang, L. Wu, K. S. Carmon, Q. J. Liu

The paper shows that the RNF43-G659Vfs41 mutation is functional and not a driver mutation in tumorigenesis, but may be a passenger mutation in MLH1-downregulated tumors.

bioRxiv · Jul 22, 2019Cancer Biology